UCB stock reports 22 percent H1 revenue growth

Published on 10/07/2026 at 14:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB stock traded at EUR 201.80 on Euronext Brussels on October 7, 2026, valuing the company at EUR 38.4 billion. BIMZELX peak sales guidance is at least EUR 7 billion.

Architektur-Render eines geschwungenen Glasgebäudes mit Reflexionsbecken und begrünter Umgebung — UCB S.A. (BE0003739530) symbolisiert durch elegantes Architektur-Render eines modernen Biopharma-Hauptsitzes mit Glasfassade, Illustration mit AI erstellt.

UCB (ISIN BE0003739530) reported H1 2026 revenue of EUR 4.27 billion, up 22 percent from H1 2025, according to Quartr. The Belgian biopharmaceutical company enters the fourth quarter with upgraded financial guidance and a larger long-term sales ambition for BIMZELX.

Revenue growth reaches EUR 4.27 billion

H1 revenue increased 22 percent year over year to EUR 4.27 billion, while EBITDA rose 68 percent, based on the H1 2026 figures summarized by Quartr. The comparison matters because it combines double-digit sales growth with faster earnings expansion, a mix that can support investment in UCB's development pipeline.

UCB's investor information lists BIMZELX sales of EUR 1.52 billion in HY 2026 and peak sales guidance of at least EUR 7 billion. The same page lists CIMZIA sales of EUR 954 million, BRIVIACT sales of EUR 327 million and RYSTIGGO sales of EUR 192 million in the period, giving the portfolio a broader base than a single-product story.

BIMZELX sets the strategic benchmark

The commercial focus is BIMZELX, which UCB identifies as its largest growth driver. At the September 23, 2026 Bank of America healthcare conference, management also cited more than 9,000 weekly scripts and said it was comfortable with consensus of EUR 3.2 billion in BIMZELX sales for 2026, according to Quartr. That figure gives investors a near-term benchmark against the longer-term peak sales target.

The portfolio also carries identifiable pressure points. UCB's investor page lists loss-of-exclusivity dates for several products, including BRIVIACT in the United States and Europe in 2026 and CIMZIA in Japan in 2026, while its pipeline includes clinical milestones extending into 2027 and beyond.

UCB stock trades below EUR 2026 high

UCB stock was trading at EUR 201.80 on Euronext Brussels on October 7, 2026 at 1:48 p.m. CEST, down 0.25 percent from EUR 202.30. The session range was EUR 199.85 to EUR 202.60, and the 52-week range was EUR 198.75 to EUR 289.50.

The market capitalization was EUR 38.4 billion on October 7, 2026, with volume of 18,732 shares. The current quote sits EUR 87.70 below the 52-week high, while the H1 growth figures and BIMZELX target provide the operating benchmarks behind the valuation.